Diamyd Medical provides information regarding changes in associated company Cellaviva

Diamyd Medical (Nasdaq Stockholm First North, DMYD B) announces that the stem cell company Cellaviva AB is to be refinanced by approximately MSEK 8.2 through the exercise of a convertible loan of about MSEK 2.7 and a capital contribution of approximately MSEK 5.5, of which Diamyd Medical’s shares amount to MSEK 1.3 and MSEK 1, respectively. Cellaviva intends to increase its focus on the development of therapeutic stem cell products. Diamyd Medical has also announced in its quarterly report, which was published today, that an impairment has been made of the previous holding.Developments in